The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato ... patients treated with Spravato should receive a dose twice a week for the first four ...

The FDA approved esketamine (Spravato) nasal spray as monotherapy ... with least-square mean differences of -5.1 with the ...

although more than one dose may be used depending on a patient's age and other factors. Spravato is approved as an adjunctive therapy administered by a nasal spray and is based on esketamine ...

In some patients, there was a measurable shift on the MADRS scale within around 24 hours of the first dose, according to J&J. That speed of onset has been held up as the main benefit for Spravato ...